Accelerated global new drug development over the past five years...Increasing proportion of biopharmaceuticals
Jul 16, 2025
While global new drug development has accelerated over the past five years, the proportion of biopharmaceuticals is steadily increasing.
According to IQVIA, a pharmaceutical market research firm, 394, or about 40% of the total 1,005 new active ingredients (NAS) released from 2005 to last year, were released between 2020 and 2024. It was analyzed that the past five years were the period when global new drug development accelerated. During this period, 273 NAS were released in the United States, an increase of 22% compared to 2015-2019.
In addition, the proportion of biopharmaceuticals among NAS released during this period recorded 42%, which increased steadily over 2005-2009 (28%), 2010-2014 (30%), and 2015-2019 (39%). By country, the proportion of biopharmaceuticals among NAS released between 2020 and 2024 was 44% in the United States, 45% in four European Union countries and the United Kingdom, 45% in Japan, and 33% in China.
There are also large differences in regional accessibility of new drugs. The United States has access to 81% of all new drugs, while major European countries have 65% of them, followed by Japan's 60%, and China's 59%. IQVIA predicts that non-original biopharmaceuticals will contribute to improving accessibility in emerging countries.
IQVIA predicts that 65 to 75 new drugs will be released annually over the next five years, and that obesity treatment and oncology will lead the growth of (pharmaceutical and bio) by 2029. In addition, global drug use is expected to grow 0.8% annually by 2029.
According to IQVIA, a pharmaceutical market research firm, 394, or about 40% of the total 1,005 new active ingredients (NAS) released from 2005 to last year, were released between 2020 and 2024. It was analyzed that the past five years were the period when global new drug development accelerated. During this period, 273 NAS were released in the United States, an increase of 22% compared to 2015-2019.
In addition, the proportion of biopharmaceuticals among NAS released during this period recorded 42%, which increased steadily over 2005-2009 (28%), 2010-2014 (30%), and 2015-2019 (39%). By country, the proportion of biopharmaceuticals among NAS released between 2020 and 2024 was 44% in the United States, 45% in four European Union countries and the United Kingdom, 45% in Japan, and 33% in China.
There are also large differences in regional accessibility of new drugs. The United States has access to 81% of all new drugs, while major European countries have 65% of them, followed by Japan's 60%, and China's 59%. IQVIA predicts that non-original biopharmaceuticals will contribute to improving accessibility in emerging countries.
IQVIA predicts that 65 to 75 new drugs will be released annually over the next five years, and that obesity treatment and oncology will lead the growth of (pharmaceutical and bio) by 2029. In addition, global drug use is expected to grow 0.8% annually by 2029.
|
This article was translated by Naver AI translator.
